Psychiatric NP Scope of Practice for ADHD in New York

You’re a psychiatrist or psychiatric nurse practitioner considering telehealth for ADHD treatment. The demand is massive — ADHD affects 8-10% of U.S. adults, and most can’t find a provider. You know you could help these patients, but one question keeps coming up: Can I legally prescribe Adderall, Ritalin, or other ADHD medications through a video visit?

The short answer in 2026: Yes, you can — but the rules are complicated, changing, and vary by state. Federal flexibilities that made telehealth ADHD prescribing possible during COVID are still in place through December 2026, but permanent regulations are coming. On top of that, each state has its own scope-of-practice rules, especially for nurse practitioners.

This guide breaks down exactly what you need to know: federal DEA requirements, state-by-state prescribing laws for the six largest psychiatric markets (California, Texas, Florida, New York, Pennsylvania, Illinois), and what’s coming next. If you’re thinking about joining a telehealth platform to treat ADHD patients, or you’re already practicing and want to make sure you’re compliant, this is your roadmap.

Federal Rules: The DEA’s Telehealth Extension Through 2026

The Ryan Haight Act Background

Before COVID-19, the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 required an in-person medical evaluation before prescribing any Schedule II controlled substance (which includes ADHD stimulants like Adderall and Ritalin). This was federal law — no exceptions for telemedicine unless you had a special DEA registration that, in practice, never existed.

That meant prescribing ADHD medications via telehealth was essentially impossible until March 2020.

COVID Emergency Waivers — Extended Through 2026

When the public health emergency hit, the DEA and HHS waived the in-person exam requirement. As of January 2, 2026, that waiver has been extended for the fourth time — it now runs through December 31, 2026.

Here’s what that means for you right now:

• You can prescribe Schedule II-V controlled substances via telehealth without any prior in-person visit, as long as:
• The prescription is for a legitimate medical purpose
• You conduct a real-time audio-visual evaluation (video visit required, not just phone)
• You’re practicing within your usual scope and standard of care
• You follow all other controlled-substance prescribing rules (e-prescribing, PDMP checks, etc.)

ADHD treatment falls squarely within this flexibility. A psychiatrist or PMHNP can diagnose ADHD and initiate stimulant therapy entirely via telehealth — no in-person visit required through the end of 2026.

What Happens After 2026? The DEA’s Permanent Rules

The DEA is working on three new permanent telemedicine rules to replace these temporary extensions. Based on the DEA’s January 2025 announcement, here’s what to expect:

1. Telemedicine Special RegistrationThe DEA will create a pathway for providers to obtain a special registration authorizing telehealth prescribing of controlled substances without an in-person exam. This registration will require:

• Mandatory nationwide PDMP checks (the DEA is building a national database)
• Strict patient identity verification during video consults
• Compliance with additional safeguards

2. Established Patient ExceptionIf you’ve seen a patient in person at least once (or they’ve been seen by another provider in your practice), you can continue prescribing via telehealth without additional requirements. The special registration is only needed for new patients you’ve never met in person.

3. Platform RegistrationTelehealth platforms (like Klarity) will need to register with the DEA. This is a corporate-level compliance requirement to prevent ‘pill mill’ operations.

The details aren’t finalized yet — the DEA received over 38,000 public comments on earlier proposals and went back to the drawing board after criticism that initial rules (like a 30-day supply limit) were too restrictive. The current approach aims to balance access with safety.

What you should do now: Continue treating ADHD patients via telehealth under the current extension. Plan to obtain the special DEA registration when it becomes available (likely in 2027) if you want to continue prescribing to new patients without in-person visits.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Rules: Where Regulations Get Complicated

Federal law sets the floor, but states can — and do — add their own requirements. Here’s what you need to know for the six largest markets for psychiatric telehealth.

California: Liberal Telehealth Laws, NPs Gaining Independence

Telehealth PrescribingCalifornia doesn’t require an in-person exam for prescribing via telehealth. State law explicitly says a telehealth evaluation can satisfy the ‘appropriate prior examination’ requirement — even asynchronous methods if clinically appropriate. For ADHD, a thorough video assessment is standard practice.

No state-level ban on prescribing Schedule II controlled substances through telemedicine. California defers to federal rules.

Key Requirements:

• PDMP: You must check California’s CURES database before the initial stimulant prescription and at least every 4 months for ongoing therapy. This is mandatory by law.
• E-prescribing: Electronic prescriptions required for controlled substances.

Scope of Practice:

• Psychiatrists (MD/DO): Full authority to prescribe ADHD medications via telehealth. Need California license and DEA registration.
• PMHNPs: California is transitioning to Full Practice Authority. By 2026, experienced NPs (with 3 years/4,600 hours under physician oversight) can practice and prescribe independently. New-grad NPs still need physician collaboration until they meet those requirements.

Bottom line for CA: One of the most provider-friendly states for telehealth ADHD care. Just make sure you’re checking CURES regularly and documenting your clinical evaluations thoroughly.

Texas: Physician-Only for ADHD Stimulants

Telehealth PrescribingTexas allows telemedicine for mental health treatment. No state ban on prescribing ADHD medications via telehealth by physicians (Texas does prohibit tele-prescribing controlled substances for chronic pain, but ADHD doesn’t fall under that).

The Big Restriction:Nurse practitioners and physician assistants in Texas cannot prescribe Schedule II controlled substances in outpatient settings. Period.

The only exceptions are extremely limited: hospital inpatient orders (≥24-hour admission), hospice care, or emergency department orders. Outpatient ADHD treatment doesn’t qualify.

This means:

• Psychiatrists (MD/DO): Can prescribe ADHD medications via telehealth with no issues
• PMHNPs: Cannot write Adderall, Ritalin, or any Schedule II stimulant prescriptions for outpatient ADHD patients. A physician must write the prescription.

Key Requirements:

• PDMP: Texas requires checks for opioids, benzos, barbiturates, and carisoprodol — stimulants aren’t technically mandated, but it’s best practice to check anyway.
• E-prescribing: Mandatory for all controlled substances in Texas (as of 2021).

Scope of Practice:NPs can prescribe Schedule III-V with physician delegation and must consult with their collaborating physician after 90 days of controlled-substance therapy. But Schedule II is off-limits for outpatient care.

Bottom line for TX: If you’re a psychiatrist, Texas is fine for telehealth ADHD care. If you’re an NP, you need a physician on your care team to handle stimulant prescriptions — or you can only treat non-stimulant ADHD cases (Strattera, Qelbree, etc.).

Florida: Clear Exception for Psychiatric Treatment

Telehealth PrescribingFlorida has explicit language in its statute: You can prescribe Schedule II controlled substances via telehealth for treatment of a psychiatric disorder. ADHD qualifies.

Florida Statutes §456.47 carves out this exception alongside inpatient, hospice, and nursing home care. This was written into law in 2019 — Florida anticipated the need for mental health telehealth access.

Key Requirements:

• PDMP: Mandatory check of Florida’s E-FORCSE database before prescribing controlled substances to patients 16 or older (except for non-refillable 3-day supplies).
• E-prescribing: Required.
• Telehealth consent: Document patient consent for telehealth services.

Out-of-State Provider Option:Florida has a unique telehealth provider registration for out-of-state practitioners. If you’re licensed in another state, you can register with Florida’s Department of Health to treat Florida patients via telehealth — including prescribing ADHD medications under the psychiatric exception — without getting a full Florida license. Requirements include clean disciplinary record, malpractice insurance, and meeting Florida’s criteria.

Scope of Practice:

• Psychiatrists (MD/DO): Full authority to prescribe via telehealth.
• PMHNPs: Can prescribe ADHD medications, but there are nuances. Florida limits APRNs to a 7-day supply of Schedule II drugs for acute conditions — unless you’re a ‘psychiatric nurse’ prescribing for mental disorders. If you’re a PMHNP with an advanced degree in psychiatric nursing and 2+ years of post-grad psych experience under a psychiatrist, the 7-day limit doesn’t apply.

However, Florida PMHNPs must practice under a protocol with a supervising psychiatrist. Florida’s 2020 independence law for primary care NPs did not extend to psychiatric NPs — you need that physician relationship.

Bottom line for FL: Florida is very clear about allowing telehealth ADHD prescribing. The psychiatric exception is explicitly in statute. Just make sure PMHNPs have proper physician oversight documented.

New York: Recently Aligned State and Federal Rules

Telehealth PrescribingNew York updated its regulations in May 2025 to explicitly allow prescribing controlled substances via telehealth consistent with federal law. Before that, NY had an older rule mirroring the Ryan Haight Act.

The New York State Department of Health now says: no controlled substance shall be prescribed before an in-person exam except when prescribing via telehealth in accordance with state and federal rules. In practice, this means as long as the DEA extension is active (through 2026), you can prescribe ADHD meds via telehealth in New York.

Key Requirements:

• PDMP: You must check New York’s I-STOP/PMP registry before prescribing any Schedule II, III, or IV controlled substance. Highly enforced — run the check for every stimulant prescription.
• E-prescribing: Mandatory for all controlled substances since 2016.

Unique Feature — 90-Day Supply Option:New York generally limits controlled-substance prescriptions to 30 days. However, for ADHD specifically, you can prescribe up to a 90-day supply of stimulants if you indicate the prescription is for ‘minimal brain dysfunction’ (the old term for ADHD) or narcolepsy by using Code B on the prescription. This applies to physicians and NPs alike — a practical efficiency for stable patients.

Scope of Practice:

• Psychiatrists (MD/DO): Full prescribing authority.
• PMHNPs: After 3,600 hours of practice experience, NPs can practice independently without a written collaborative agreement (though they maintain a ‘collaborative relationship’ with a physician). New York NPs can prescribe Schedule II-V controlled substances with their own DEA registration. No state-specific quantity limits for NPs beyond what applies to all prescribers.

Bottom line for NY: The May 2025 regulatory update removed state-level barriers. Make sure you’re checking the PMP every time and using e-prescribing. The 90-day supply option is a real advantage for ongoing ADHD management.

Pennsylvania: 30-Day Limit for NPs

Telehealth PrescribingPennsylvania doesn’t have a state law prohibiting telehealth prescribing of controlled substances beyond federal requirements. The state’s medical boards have issued guidelines stating that a valid patient-provider relationship can be established through telemedicine, and prescribing is acceptable if it meets the standard of care.

Key Requirements:

• PDMP: Pennsylvania requires checking the state PDMP before the initial prescription of any controlled substance in a new course of treatment, and mandates checks for each opioid or benzodiazepine prescription. For stimulants, it’s required initially and encouraged for ongoing prescriptions.
• E-prescribing: Mandatory for controlled substances since October 2019 (Act 96 of 2018).

Scope of Practice:Pennsylvania is a restricted practice state for nurse practitioners.

• Psychiatrists (MD/DO): Full authority to prescribe ADHD medications via telehealth.
• PMHNPs: Must have a collaborative agreement with a physician. The critical restriction: CRNPs can prescribe Schedule II controlled substances for up to a 30-day supply only. Any continuation beyond 30 days requires physician approval.

The regulation (49 Pa. Code Chapter 21) explicitly states this. In practice, an NP treating ADHD can write the initial one-month prescription, but before month two, the collaborating physician needs to review and approve continuation (this doesn’t mean the patient sees the MD, but the MD must OK the refill).

For Schedule III-IV, NPs can prescribe up to 90 days.

Bottom line for PA: Straightforward for psychiatrists. For NPs, the 30-day Schedule II limit means you need a collaborative physician actively involved in ADHD stimulant management — either co-managing cases or at minimum reviewing/approving continuation monthly.

Illinois: Two-Tier System for NPs

Telehealth PrescribingIllinois broadly permits telehealth for prescribing controlled substances with no state-specific ban beyond federal requirements. The Illinois Telehealth Act (amended 2021) ensures parity and allows establishing patient relationships via telemedicine.

Key Requirements:

• Controlled Substance License: All prescribers must have an Illinois Controlled Substance License in addition to their DEA registration (apply through IL DFPR).
• PDMP: Illinois mandates checking the PMP for opioids and first-time benzos. Not explicitly required for stimulants by statute, but best practice is to check.
• E-prescribing: Required.

Scope of Practice — The Two-Tier System:Illinois offers a pathway to Full Practice Authority (FPA) for experienced APRNs, creating two distinct categories:

1. APRNs Under Collaboration (Standard Practice):

• Must have written collaborative agreement with a physician
• Can prescribe Schedule II for up to 30 days (physician must approve continuation beyond 30 days)
• Physician must review Schedule II prescribing monthly
• Stimulants fall under this 30-day limit

2. APRNs with Full Practice Authority (FPA):

• After 4,000 hours of clinical practice under collaboration + 250 hours of CE/training, NPs can apply for FPA
• FPA APRNs can prescribe independently, including Schedule II stimulants, without physician collaboration
• Exception: For Schedule II narcotic drugs (opioids) and benzodiazepines, even FPA NPs need a monthly physician consultation — but stimulants are non-narcotic Schedule IIs, so no consultation requirement

This is a significant distinction. A PMHNP with FPA in Illinois can manage ADHD patients and prescribe stimulants entirely independently via telehealth.

Other Prescribers:Illinois allows ‘Prescribing Psychologists’ with physician collaboration, but they’re limited to non-controlled psychotropic meds and cannot prescribe Schedule II — so ADHD medication management stays with MD/DO, NPs, or PAs.

Bottom line for IL: If you’re a psychiatrist, full authority. If you’re an NP, aim for FPA status — it removes the 30-day limit and physician-approval requirement for ADHD stimulants. If you haven’t reached FPA yet, expect monthly physician involvement in Schedule II cases.

Summary Table: State-by-State Telehealth ADHD Prescribing Rules

What This Means for Your Practice

If You’re a Psychiatrist (MD/DO):

You have full authority to treat ADHD patients via telehealth in all six states covered here (and most others). The main variables are:

• Licensure: You need a medical license in the patient’s state (some states like PA are in the Interstate Medical Licensure Compact, which can expedite this)
• PDMP compliance: Check the state’s prescription monitoring database as required (usually mandatory)
• E-prescribing: Use EPCS-enabled systems
• Standard of care: Document thorough evaluations (clinical interview, DSM criteria, consideration of differential diagnoses)

The federal extension through 2026 gives you certainty. Plan for the DEA’s special registration requirement when it arrives — but that’s likely still 12+ months away.

If You’re a Psychiatric Nurse Practitioner:

Your scope depends entirely on which state you’re practicing in:

Full Authority States:

• California (if experienced/FPA)
• Illinois (if FPA status)
• New York (if 3,600+ hours experience)

In these states, you can diagnose and treat ADHD independently, including prescribing stimulants via telehealth.

Collaboration Required, But Can Prescribe:

• Pennsylvania (30-day limit, physician approval for continuation)
• Illinois (if not FPA — 30-day limit, monthly MD review)
• Florida (psychiatrist protocol required; no quantity limit for psych NPs)

In these states, you can prescribe ADHD medications but need an active collaborative relationship with a physician. The physician doesn’t need to see every patient, but they must be involved in oversight and approvals.

Cannot Prescribe ADHD Stimulants:

• Texas (NPs barred from Schedule II outpatient prescribing)

In Texas, you can evaluate ADHD patients and manage non-stimulant treatments (Strattera, Qelbree, Intuniv), but a physician must write any stimulant prescriptions.

The Economics of Patient Acquisition: Why Platforms Matter

Let’s talk about the business reality of building an ADHD practice via telehealth.

DIY Marketing Reality Check:Many providers think, ‘I’ll just get some patients through Google Ads or a Psychology Today listing.’ Here’s what that actually costs:

• Google Ads: Mental health keywords run $15-40+ per click. Most clicks don’t convert to booked patients. A realistic cost per booked patient through PPC is $200-400+ when you factor in click costs, ad optimization, and conversion rates.

• SEO: Takes 6-12 months of consistent investment (content, technical optimization, link building) before generating meaningful patient flow. Most solo providers don’t have the expertise or patience for this timeline.

• Directory Listings: Psychology Today charges monthly fees and you compete with hundreds of other providers on the same page. Zocdoc charges $35-100+ per booking, but monthly subscription fees add up. Total cost including subscription: several hundred dollars monthly with uncertain results.

• Full Marketing Budget: Providers who successfully build patient flow through DIY marketing typically spend $3,000-5,000+ monthly when you include all costs — agency fees, ad spend, staff time to handle and qualify leads, no-show rates from cold leads, months of testing and optimization, and failed campaigns.

The Platform Economics Alternative:Telehealth platforms like Klarity use a fundamentally different model — a pay-per-appointment structure where you only pay when you actually see a qualified patient.

Here’s why that matters:

• No upfront marketing spend or monthly subscription fees — zero risk if you want to start slow or scale gradually
• Pre-qualified patients already matched to your specialty and availability (ADHD-specific patient flow)
• No wasted spend on clicks that don’t convert or directories where patients never call
• Built-in infrastructure — telehealth platform, scheduling, EHR, e-prescribing (no separate technology costs)
• Both insurance and cash-pay patient streams
• You control your schedule — only pay when patients actually show up

The standard listing fee per patient covers patient acquisition that would cost you far more to generate yourself. Instead of gambling $3,000-5,000 monthly on marketing channels with uncertain ROI, you pay a predictable, scalable fee only when revenue comes in.

Can DIY marketing work? Yes — IF you have the budget, expertise, and patience to invest for 6-12 months before seeing results. Many providers eventually build cost-effective patient acquisition this way. But for most psychiatrists and NPs — especially those starting out, building a telehealth practice alongside in-person work, or scaling quickly — a platform that handles patient acquisition removes the risk entirely and delivers immediate patient flow.

Practical Compliance Checklist for Telehealth ADHD Prescribing

Before You Start:

• [ ] Verify you’re licensed in the patient’s state
• [ ] Have DEA registration covering that state
• [ ] Obtain any additional state requirements (IL controlled substance license, NY bureau narcotic number, etc.)
• [ ] Set up e-prescribing with EPCS capability
• [ ] Register for state PDMP access

For Each New Patient:

• [ ] Conduct live video evaluation (audio-visual required)
• [ ] Document thorough ADHD assessment (DSM-5 criteria, symptom history, functional impairment, rule-outs)
• [ ] Check state PDMP before prescribing (required in most states)
• [ ] Verify patient identity and location during consult
• [ ] Document consent for telehealth treatment
• [ ] Issue electronic prescription with appropriate diagnosis codes

Ongoing Management:

• [ ] Re-check PDMP periodically (every 4 months in CA; each prescription in NY; best practice quarterly elsewhere)
• [ ] Document treatment response and any side effects
• [ ] For NPs in restricted states: obtain physician collaboration/approval as required
• [ ] Maintain records per state requirements (typically 7-10 years)
• [ ] Stay current on DEA rule changes (subscribe to DEA updates or work with a compliance-focused platform)

What’s Coming: Preparing for Post-2026 Rules

The DEA extension expires December 31, 2026. Here’s what you should be watching for:

Timeline:

• 2026: Continue under current flexibilities
• Late 2026/Early 2027: DEA expected to finalize permanent rules
• 2027: Likely implementation of telemedicine special registration

What to Prepare For:

1. Special Registration Application: Expect a new DEA form and possibly a fee for the telemedicine special registration
2. Enhanced PDMP Requirements: The DEA is building a national PDMP hub — you may need to check this in addition to state databases
3. Platform Registration: If you work through a telehealth company, ensure they’re registered with the DEA
4. Possible Periodic In-Person Requirements: The DEA may require an in-person visit at some interval (annually?) for ongoing stimulant patients — though this is uncertain

What Probably Won’t Change:

• Video evaluation will remain acceptable (replacing in-person for initial assessment)
• Standard-of-care requirements (thorough diagnosis, appropriate prescribing)
• State scope-of-practice rules (the DEA rules are federal; state NP restrictions will still apply)

The DEA’s stated goal is to preserve telehealth access while adding safeguards. Based on their January 2025 announcement and industry feedback, the final rules should be workable for legitimate practices.

FAQ: Common Questions from ADHD Prescribers

Q: Can I prescribe Adderall via telehealth right now in 2026?A: Yes, through December 31, 2026, under the federal extension. You must use live video, meet standard of care, and follow all state requirements (licensing, PDMP checks, e-prescribing).

Q: Do I need to see the patient in person eventually?A: Not under current federal rules through 2026. Some states have no in-person requirement at all if telehealth meets the standard of care. Post-2026 DEA rules may impose periodic in-person visits — we don’t know yet.

Q: Can I prescribe to patients in multiple states?A: Yes, but you need a license in each state where the patient is located at the time of the visit (not where they’re from, but where they physically are). Some states (PA, others) are in the Interstate Medical Licensure Compact which speeds up multi-state licensing for physicians.

Q: What about phone-only visits?A: Federal rules require audio-visual (video) for prescribing controlled substances via telemedicine. Audio-only is not sufficient for initiating stimulant therapy under current DEA guidance.

Q: Are non-stimulant ADHD medications easier to prescribe via telehealth?A: Yes. Medications like Strattera (atomoxetine), Qelbree (viloxazine), Intuniv (guanfacine), and Kapvay (clonidine) are not controlled substances, so the Ryan Haight Act and DEA rules don’t apply. You follow normal prescribing standards and state telehealth rules, but no PDMP checks or special DEA requirements.

Q: What happens if I don’t check the PDMP?A: In states where it’s mandatory (CA, NY, FL for controlled substances), failure to check can result in disciplinary action by the medical board, including license suspension. It’s also a liability issue — if a patient is ‘doctor shopping’ and you don’t catch it, you could face DEA scrutiny.

Q: Can I treat children with ADHD via telehealth?A: Yes, but ensure parental/guardian consent and involvement. Some states have specific rules about treating minors via telehealth (usually requiring parent presence or consent). Florida, for instance, requires PMHNP collaboration with a pediatrician or psychiatrist for psychotropic meds in kids. Check your state’s rules on minor consent.

Q: What if I’m an NP in a state like Texas where I can’t prescribe stimulants?A: You have options: (1) Treat ADHD with non-stimulant medications within your scope, or (2) Work with a physician collaborator who can write the stimulant prescriptions while you manage the overall care. Many telehealth platforms have models to support this.

Joining Klarity: Built for ADHD Provider Compliance and Patient Flow

If you’re reading this, you already know there’s massive demand for ADHD treatment. The regulatory complexity is the barrier — that, and finding qualified patients.

What Klarity Handles:

• Pre-qualified patient matching: Patients seeking ADHD evaluation and treatment, matched to your availability and state license
• Compliance infrastructure: Built-in e-prescribing, PDMP integration, documentation templates that meet state requirements
• State-specific protocols: For restrictive states (Texas NP rules, Pennsylvania 30-day limits), we have workflows to ensure compliance
• No marketing risk: Pay-per-appointment model means you don’t spend thousands hoping to get patients — you pay only when qualified patients book with you
• Multi-state licensing support: Guidance on expanding to additional states if you want to scale

Why ADHD Providers Choose Platforms Over DIY:The reality is that building a telehealth ADHD practice from scratch means:

• 6-12 months of marketing investment before meaningful patient flow
• $3,000-5,000+ monthly in ad spend and optimization
• Navigating separate technology vendors (EHR, e-prescribing, video platform)
• Fielding unqualified leads and no-shows from cold advertising
• Keeping up with 50 different state regulations on your own

Or you can join a platform that’s already solved these problems and delivers qualified ADHD patients to your schedule — you just provide the clinical care.

Ready to start treating ADHD patients via telehealth? Learn more about joining Klarity’s provider network and see how we handle compliance, patient acquisition, and infrastructure so you can focus on what you do best.

[Learn more about joining Klarity →]

Sources and Citations

All regulatory information in this guide has been verified against official government sources and current statutes as of February 2026. Below are the primary sources consulted:

Federal Sources

1. DEA & HHS Press Release – Extension of Telemedicine Flexibilities Through 2026 (January 2, 2026) – Official announcement of fourth extension allowing Schedule II-V prescribing via telehealth through December 31, 2026 (Healthcare Dive coverage)

2. DEA Press Release – Three New Telemedicine Rules (January 16, 2025) – Official announcement of proposed permanent rules including telemedicine special registration, PDMP requirements, and platform oversight (DEA.gov)

State Sources

California:

3. California Business & Professions Code §2242 & §4067 – Statutory authority for telehealth prescribing without in-person exam requirement (Center for Connected Health Policy summary)

4. RxAgent NP Prescriptive Authority Guide (Updated December 28, 2025) – Comprehensive analysis of California’s transition to Full Practice Authority for NPs (RxAgent.co)

Texas:

5. Texas Board of Nursing – APRN Practice FAQ – Official guidance confirming NPs cannot prescribe Schedule II controlled substances in outpatient settings (Texas BON)

Florida:

6. Florida Statutes §456.47 – Telehealth law with explicit exception for prescribing Schedule II substances for psychiatric disorders (Florida Legislature)

7. Florida Statutes §464.012 – Nursing prescribing authority including 7-day limit exception for psychiatric nurses (Florida Legislature)

New York:

8. New York State Department of Health – Bureau of Narcotic Enforcement Guidance (Effective May 21, 2025) – Updated regulations aligning state controlled substance prescribing rules with federal telehealth allowances (Ninth District summary)

Pennsylvania:

9. 49 Pennsylvania Code Chapter 21 – CRNP prescriptive authority regulations including 30-day Schedule II limit (Pennsylvania Code and Bulletin)

Illinois:

10. 225 ILCS 65/65-40 & Illinois Administrative Code – Nurse Practice Act rules detailing collaboration requirements, 30-day Schedule II limits, and Full Practice Authority pathway (Illinois General Assembly)

Last updated: February 10, 2026. Regulations are subject to change. Providers should verify current requirements with their state medical boards and monitor DEA announcements for updates to federal telehealth prescribing rules.

Source:

• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,II%20to%20Schedule%20V%20drugs
• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,to%20hash%20out%20permanent%20regulations
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Proposed%20DEA%20rules%20create%20a,for%20telemedicine%20prescribing
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=there%20any%20settings%20other%20than,may%20prescribe%20Schedule%20II%20controlled
• https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth#:~:text=as%20such%20terms%20are%20defined,the%20use%20of%20electronic%20prescribing
• https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html#:~:text=,
• https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300#:~:text=match%20at%20L5536%203,collaborating%20physician%20or%20podiatric%20physician
• https://rxagent.co/blog/np-prescribing-authority#:~:text=However%2C%20,3
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Prescribing%2C%20dispensing%2C%20or%20furnishing%20dangerous,the%20appropriate%20standard%20of%20care